# LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

Source: https://onco.cc/trials/nct06193902/  
OnCo record `nct06193902` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LEU011 in advanced solid tumours, run by Leucid Bio, now recruiting.

## Summary

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. is a phase 1/2 interventional study registered as NCT06193902 by Leucid Bio, with 17 participants planned, started 2023-11-13 and due to reach its primary completion in 2029-05. Interventions recorded: LEU011.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06193902
- Phase: 1/2
- Setting: A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours
- Sponsor: Leucid Bio
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT06193902: https://clinicaltrials.gov/study/NCT06193902

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06193902.json